Dana-Farber
Precede Biosciences Debuts Chromatin-Based Liquid Biopsy Platform Backed by New Data at ESMO
Premium
The firm has begun working with pharma, using its technology to identify and monitor transcriptionally regulated drug targets. It is also eyeing multiple clinical diagnostic applications.
Liquid Biopsy Company Precede Biosciences Emerges From Stealth With $57M in Financing
The firm's technology detects genome-wide patterns of gene activation, promotion, and methylation in circulating chromatin from a 1-mL plasma sample.
Aspira Women's Health Licenses Dana-Farber microRNA Signature; Firm Executes Reverse Stock Split
Aspira Women's Health has been evaluating Dana-Farber's microRNA technology for ovarian cancer detection since early 2021.
Cancer Centers Nudge Oncologists Toward DPYD Testing as PGx Supporters Push For Guidelines Change
Premium
Several institutions, swayed by PGx experts and advocates, are setting up DPYD testing to avoid deadly chemo toxicities in patients even though the NCCN and FDA don't back it.
New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur
Premium
Investigators shared results of a study this week in which ctDNA residual disease testing gave advance notice of late recurrences in surgically resected HR+ HER2- patients.